Table 2. Chemotherapy regimens and median survival time from the start of each line of chemotherapy.
| Variables | Total, n=271 |
|---|---|
| First-line regimen, n (%) | |
| S-1 + cisplatin | 144 (53.1) |
| S-1 + oxaliplatin | 24 (8.9) |
| S-1 monotherapy | 73 (26.9) |
| Trastuzumab containing regimen | 7 (2.6) |
| Others | 23 (8.5) |
| Second-line regimen, n (%) | |
| Paclitaxel + ramucirumab | 12 (8.1) |
| Paclitaxel or docetaxel monotherapy | 77 (52.0) |
| Irinotecan monotherapy | 35 (23.6) |
| Others | 24 (16.2) |
| Third-line regimen, n (%) | |
| Irinotecan monotherapy | 35 (49.3) |
| Paclitaxel or docetaxel monotherapy | 23 (32.4) |
| Nivolumab | 1 (1.4) |
| Others | 12 (16.9) |
| Survival time from the start of the first line, median [IQR], days | 234 [133–486] |
| Survival time from the start of the second line, median [IQR], days | 166 [102–323] |
| Survival time from the start of the third line, median [IQR], days | 151 [87–239] |
IQR, interquartile range.